Rukshan Ahamed Mohamed Rafeek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rukshan Ahamed Mohamed Rafeek has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Natkunam Ketheesan
School of Science and Technology, University of New England, Armidale, Australia
8 shared publications - Ailin Lepletier
Institute for Biomedicine and Glycomics, Griffith University, Gold Coast, QLD 4215, Australia
3 shared publications - Faseeha Noordeen
Department of Microbiology, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri Lanka
3 shared publications - Manisha Pandey
Griffith University
3 shared publications - Michael F. Good
Griffith University
3 shared publications David J. McMillan
School of Science & Technology University of New England Armidale New South Wales Australia
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Wiley in Animal Models and Experimental Medicine
Antibodies generated against recombinant streptococcal inhibitor of complement do not trigger detectable renal pathology in a Lewis rat model
Background: Post‐streptococcal glomerulonephritis (PSGN) is an immune‐mediated sequela of group A streptococcal (GAS) infections, with nephritogenic GAS antigens implicated in its pathogenesis. Seroepidemiological evidence also implicates GAS streptococcal inhibitor of complement (SIC) in the development of PSGN. This association is supported by elevated anti‐SIC antibody responses in patients with PSGN, suggesting a possible role for these antibodies in disease pathogenesis. Methods: To investigate whether antibodies generated against SIC are associated with renal pathology, Lewis rats were administered recombinant SIC (rSIC), its domain containing the long repeat region (LRR) and proline‐rich region (PRR), or rSIC combined with inactivated whole‐cell GAS (IWG) in a series of experiments. Serum antibody responses were evaluated using enzyme‐linked immunosorbent assays. Renal alterations were assessed by biochemical analyses of serum and urinary albumin, creatinine, and urea; urinalysis for microhematuria and albumin‐to‐creatinine ratio; histopathology; and immunofluorescence analysis of immunoglobulin G (IgG) and complement C3 deposition. Systemic complement activation was evaluated by measuring serum C3a levels. Results: Although robust anti‐SIC antibody responses ( p < 0.0001) were observed in all rats exposed to the various SIC formulations or domain, no renal functional impairment, histopathological injury, urinary abnormalities, or significant alterations in serum C3a levels were identified. In the absence of overt renal abnormalities, immunofluorescence revealed only focal low‐grade glomerular IgG deposition but no detectable C3 deposition. Conclusions: In this Lewis rat model, antibodies to rSIC did not drive PSGN‐like renal pathology. This suggests that SIC‐specific humoral responses alone may be insufficient for disease development, potentially reflecting the multifactorial nature of PSGN pathogenesis.
- 16 November 2026
- Published by Wiley in Animal Models and Experimental Medicine
Open AccessAntibodies generated against recombinant streptococcal inhibitor of complement do not trigger detectable renal pathology in a Lewis rat model
Background: Post‐streptococcal glomerulonephritis (PSGN) is an immune‐mediated sequela of group A streptococcal (GAS) infections, with nephritogenic GAS antigens implicated in its pathogenesis. Seroepidemiological evidence also implicates GAS streptococcal inhibitor of complement (SIC) in the development of PSGN. This association is supported by elevated anti‐SIC antibody responses in patients with PSGN, suggesting a possible role for these antibodies in disease pathogenesis. Methods: To investigate whether antibodies generated against SIC are associated with renal pathology, Lewis rats were administered recombinant SIC (rSIC), its domain containing the long repeat region (LRR) and proline‐rich region (PRR), or rSIC combined with inactivated whole‐cell GAS (IWG) in a series of experiments. Serum antibody responses were evaluated using enzyme‐linked immunosorbent assays. Renal alterations were assessed by biochemical analyses of serum and urinary albumin, creatinine, and urea; urinalysis for microhematuria and albumin‐to‐creatinine ratio; histopathology; and immunofluorescence analysis of immunoglobulin G (IgG) and complement C3 deposition. Systemic complement activation was evaluated by measuring serum C3a levels. Results: Although robust anti‐SIC antibody responses ( p < 0.0001) were observed in all rats exposed to the various SIC formulations or domain, no renal functional impairment, histopathological injury, urinary abnormalities, or significant alterations in serum C3a levels were identified. In the absence of overt renal abnormalities, immunofluorescence revealed only focal low‐grade glomerular IgG deposition but no detectable C3 deposition. Conclusions: In this Lewis rat model, antibodies to rSIC did not drive PSGN‐like renal pathology. This suggests that SIC‐specific humoral responses alone may be insufficient for disease development, potentially reflecting the multifactorial nature of PSGN pathogenesis.
- Open Access
- 22 August 2025
- Published by MDPI AG in Proceedings
- Vol. 124 (1) , 21
Low-Dose Interleukin-2 Therapy: A Transformative Approach for the Management of Autoimmune Complications Associated with Streptococcus pyogenes Infections
Acute rheumatic fever is an autoimmune inflammatory reaction to Streptococcus pyogenes infections, leading to progressive heart valve damage and rheumatic heart disease (RHD)
- 22 August 2025
- Published by MDPI AG in Proceedings
- Vol. 124 (1) , 21
Open AccessLow-Dose Interleukin-2 Therapy: A Transformative Approach for the Management of Autoimmune Complications Associated with Streptococcus pyogenes Infections
Acute rheumatic fever is an autoimmune inflammatory reaction to Streptococcus pyogenes infections, leading to progressive heart valve damage and rheumatic heart disease (RHD)
- 13 August 2025
- Published by Springer Nature in Nature Reviews Cardiology
A transformative preclinical model of rheumatic heart disease
- 13 August 2025
- Published by Springer Nature in Nature Reviews Cardiology
A transformative preclinical model of rheumatic heart disease
- Open Access
- 21 July 2025
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 13 (4) , e70155
Sulphonylureas as Adjunct Therapeutic Agents in the Treatment of Autoimmune Conditions: A Narrative Review
A rapid and cost‐effective arm of the drug discovery and development process is finding new uses for existing drugs. Initially used as antibacterial agents, sulphonylureas were repurposed for the treatment of type 2 diabetes due to their hypoglycemic side effects. Their primary mechanism of action is mediated by binding to sulphonylurea receptors (SUR), which are atypical adenosine triphosphate binding cassette transporters in pancreatic beta cells. This interaction inhibits ATP‐sensitive potassium channels to promote insulin release. Off‐target actions of sulphonylureas identified in recent studies have demonstrated a range of anti‐inflammatory properties mediated by modulation of the nucleotide‐binding oligomerization domain‐like receptor pyrin domain‐containing protein 3 inflammasomes. Inflammasomes are cytosolic protein complexes that assemble in response to infection or stress‐associated stimuli, activating inflammatory responses, and are the primary source of pro‐inflammatory cytokines. Sulphonylureas and their derivatives have been shown to inhibit various stages of inflammasome activation, leading to the reduction of pro‐inflammatory mediators, including IL‐1β and IL‐18. Recent evidence demonstrates that these agents reduced inflammatory responses, disease severity, and progression in various preclinical autoimmune and inflammatory models. In this narrative review, we consider the complexity of autoimmune conditions and the limited treatment options, and highlight the potential value of repurposing sulphonylureas and their derivatives as adjunct therapeutics for autoimmune conditions.
- 21 July 2025
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 13 (4) , e70155
Open AccessSulphonylureas as Adjunct Therapeutic Agents in the Treatment of Autoimmune Conditions: A Narrative Review
A rapid and cost‐effective arm of the drug discovery and development process is finding new uses for existing drugs. Initially used as antibacterial agents, sulphonylureas were repurposed for the treatment of type 2 diabetes due to their hypoglycemic side effects. Their primary mechanism of action is mediated by binding to sulphonylurea receptors (SUR), which are atypical adenosine triphosphate binding cassette transporters in pancreatic beta cells. This interaction inhibits ATP‐sensitive potassium channels to promote insulin release. Off‐target actions of sulphonylureas identified in recent studies have demonstrated a range of anti‐inflammatory properties mediated by modulation of the nucleotide‐binding oligomerization domain‐like receptor pyrin domain‐containing protein 3 inflammasomes. Inflammasomes are cytosolic protein complexes that assemble in response to infection or stress‐associated stimuli, activating inflammatory responses, and are the primary source of pro‐inflammatory cytokines. Sulphonylureas and their derivatives have been shown to inhibit various stages of inflammasome activation, leading to the reduction of pro‐inflammatory mediators, including IL‐1β and IL‐18. Recent evidence demonstrates that these agents reduced inflammatory responses, disease severity, and progression in various preclinical autoimmune and inflammatory models. In this narrative review, we consider the complexity of autoimmune conditions and the limited treatment options, and highlight the potential value of repurposing sulphonylureas and their derivatives as adjunct therapeutics for autoimmune conditions.
- Open Access
- 11 July 2025
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 13 (7) , e70221
Inflammatory Responses Potentiate GAS M Protein Induced Cardiac Damage in an Experimental Model of Rheumatic Heart Disease
Aim: Acute rheumatic fever (ARF) and Rheumatic heart disease (RHD) are autoimmune sequalae, that develops in a proportion of individuals exposed to group A streptococcal infection. The autoimmune pathology of ARF/RHD is multifactorial. Both host and pathogen‐associated factors including genetic predisposition, inflammatory responses, tissue cross‐reactive antibodies and T‐cells contribute to disease development and progression. Hitherto, the role of inflammatory responses in ARF/RHD has never been demonstrated in animal models. In this study for the first time, using the Rat Autoimmune valvulitis model of RHD, we demonstrate the requirement for inflammatory responses in promoting cardiac damage in ARF/RHD.Methods: To determine the role of inflammatory responses we used Bordetella pertussis toxin (BPTx) as an adjuvant to enhance the inflammatory responses initiated by GAS M protein.Results: Lewis rats injected with GAS rM5 emulsified in Complete Freund's Adjuvant (CFA) and co‐adjuvant BPTx, had enhanced valvulitis and inflammatory changes as shown by; (a) elevated levels of circulating inflammatory cytokines; (b) functional changes characterized by a prolonged P‐R interval in electrocardiography, (c) enhanced cross‐reactive antibody production against cardiac and connective tissue proteins; and (d) increased infiltration of IFN‐γ+ and IL‐17A+ secreting leukocytes into myocardium and valvular tissues.Conclusion: These studies have established that in addition to exposure to GAS M protein, BPTx accelerate the inflammatory and autoimmune processes leading to cardiac damage. These observations substantiate the hypothesis that, in susceptible individuals robust inflammatory responses facilitate the progression of ARF/RHD.
- 11 July 2025
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 13 (7) , e70221
Open AccessInflammatory Responses Potentiate GAS M Protein Induced Cardiac Damage in an Experimental Model of Rheumatic Heart Disease
Aim: Acute rheumatic fever (ARF) and Rheumatic heart disease (RHD) are autoimmune sequalae, that develops in a proportion of individuals exposed to group A streptococcal infection. The autoimmune pathology of ARF/RHD is multifactorial. Both host and pathogen‐associated factors including genetic predisposition, inflammatory responses, tissue cross‐reactive antibodies and T‐cells contribute to disease development and progression. Hitherto, the role of inflammatory responses in ARF/RHD has never been demonstrated in animal models. In this study for the first time, using the Rat Autoimmune valvulitis model of RHD, we demonstrate the requirement for inflammatory responses in promoting cardiac damage in ARF/RHD.Methods: To determine the role of inflammatory responses we used Bordetella pertussis toxin (BPTx) as an adjuvant to enhance the inflammatory responses initiated by GAS M protein.Results: Lewis rats injected with GAS rM5 emulsified in Complete Freund's Adjuvant (CFA) and co‐adjuvant BPTx, had enhanced valvulitis and inflammatory changes as shown by; (a) elevated levels of circulating inflammatory cytokines; (b) functional changes characterized by a prolonged P‐R interval in electrocardiography, (c) enhanced cross‐reactive antibody production against cardiac and connective tissue proteins; and (d) increased infiltration of IFN‐γ+ and IL‐17A+ secreting leukocytes into myocardium and valvular tissues.Conclusion: These studies have established that in addition to exposure to GAS M protein, BPTx accelerate the inflammatory and autoimmune processes leading to cardiac damage. These observations substantiate the hypothesis that, in susceptible individuals robust inflammatory responses facilitate the progression of ARF/RHD.
- Open Access
- 9 April 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (4) , e0382324
Low-dose interleukin 2 therapy halts the progression of post-streptococcal autoimmune complications in a rat model of rheumatic heart disease
Acute rheumatic fever (ARF) is an autoimmune disease triggered by antibodies and T cells targeting the group A Streptococcus (GAS, Strep A) bacterium, often leading to rheumatic heart disease (RHD) and Sydenham’s chorea. Long-term monthly penicillin injections are recognized as a cornerstone of public health programs to prevent Strep A reinfection and progression of ARF. However, compliance is poor, and better tools are required to slow disease progression. Preclinical evidence suggests that this can be achieved. Using a rat model that replicates post-streptococcal autoimmune complications, we explored the potential of low-dose interleukin-2 (LD-IL-2) as an immunotherapeutic intervention for ARF/RHD. In this model, injections of recombinant M protein from Strep A type 5 (rM5) to Lewis rats induce cardiac tissue inflammation, conduction abnormalities, and cross-reactive antibodies against cardiac and brain proteins central to disease pathogenesis. In animals injected with rM5 and treated with LD-IL-2, no cardiac functional or histological changes was observed. LD-IL-2 therapy effectively reduced the production of cross-reactive antibodies raised against host proteins and significantly increased regulatory T cells in the mediastinal lymph nodes. These novel findings suggest that LD-IL-2 will be an effective immunotherapeutic agent for treating ARF and has the potential to replace the standard monthly penicillin injections. IMPORTANCE: Post-streptococcal autoimmune syndromes, including acute rheumatic fever, rheumatic heart disease, and Sydenham’s chorea, represent a significant yet often under-recognized health and economic burden. This is especially true in low-income countries and among Indigenous populations in high-income nations, where the disease burden is most severe. These conditions arise from an autoimmune response to group A Streptococcus infections, leading to long-term health complications, disability, and premature death. Despite their widespread impact, no vaccine is currently available to prevent reinfections, and no specific therapy exists to treat the resulting autoimmune process. This study uses a rat model of rheumatic heart disease to evaluate the potential of low-dose interleukin 2 therapy in improving clinical outcomes and reducing the incidence of autoimmune diseases triggered by streptococcal infections.
- 9 April 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (4) , e0382324
Open AccessLow-dose interleukin 2 therapy halts the progression of post-streptococcal autoimmune complications in a rat model of rheumatic heart disease
Acute rheumatic fever (ARF) is an autoimmune disease triggered by antibodies and T cells targeting the group A Streptococcus (GAS, Strep A) bacterium, often leading to rheumatic heart disease (RHD) and Sydenham’s chorea. Long-term monthly penicillin injections are recognized as a cornerstone of public health programs to prevent Strep A reinfection and progression of ARF. However, compliance is poor, and better tools are required to slow disease progression. Preclinical evidence suggests that this can be achieved. Using a rat model that replicates post-streptococcal autoimmune complications, we explored the potential of low-dose interleukin-2 (LD-IL-2) as an immunotherapeutic intervention for ARF/RHD. In this model, injections of recombinant M protein from Strep A type 5 (rM5) to Lewis rats induce cardiac tissue inflammation, conduction abnormalities, and cross-reactive antibodies against cardiac and brain proteins central to disease pathogenesis. In animals injected with rM5 and treated with LD-IL-2, no cardiac functional or histological changes was observed. LD-IL-2 therapy effectively reduced the production of cross-reactive antibodies raised against host proteins and significantly increased regulatory T cells in the mediastinal lymph nodes. These novel findings suggest that LD-IL-2 will be an effective immunotherapeutic agent for treating ARF and has the potential to replace the standard monthly penicillin injections. IMPORTANCE: Post-streptococcal autoimmune syndromes, including acute rheumatic fever, rheumatic heart disease, and Sydenham’s chorea, represent a significant yet often under-recognized health and economic burden. This is especially true in low-income countries and among Indigenous populations in high-income nations, where the disease burden is most severe. These conditions arise from an autoimmune response to group A Streptococcus infections, leading to long-term health complications, disability, and premature death. Despite their widespread impact, no vaccine is currently available to prevent reinfections, and no specific therapy exists to treat the resulting autoimmune process. This study uses a rat model of rheumatic heart disease to evaluate the potential of low-dose interleukin 2 therapy in improving clinical outcomes and reducing the incidence of autoimmune diseases triggered by streptococcal infections.
- Open Access
- 10 March 2025
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (6) , 1138-1145
Disruption of the blood–brain barrier contributes to neurobehavioral changes observed in rheumatic heart disease
Sydenham chorea (SC) is the neurological manifestation associated with acute rheumatic fever (ARF). ARF and rheumatic heart disease (RHD) are autoimmune complications triggered by a group A streptococcal (GAS) infection. In ARF/RHD and SC, tissue cross‐reactive antibodies and T‐cells generated against GAS antigens have been implicated in the pathogenesis. In SC, antibodies against GAS antigens are known to cross‐react with neuronal proteins causing neurological manifestations including choreiform movements and neuropsychiatric symptoms such as irritability, attention deficit, and obsessive‐compulsive disorder. Previous studies in a rat autoimmune valvulitis (RAV) model of RHD, have shown that injection of streptococcal M protein could cause both cardiac and neurological symptoms. In this study it was shown that adoptive transfer of serum with anti‐GAS M antibodies to naive rats caused carditis but failed to demonstrate neurobehavioral symptoms. However, when the blood–brain barrier (BBB) was disrupted using lipopolysaccharide, all animals that received anti‐GAS M protein antibodies, developed neurobehavioral defects in addition to carditis. This highlights that impaired BBB integrity is essential for the development of neurobehavioral symptoms. The use of the RAV model and the disruption of BBB required for the development of neurobehavioral changes provides a platform to further investigate the mechanisms that lead to antibodies binding to basal ganglia structures that cause SC.
- 10 March 2025
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (6) , 1138-1145
Open AccessDisruption of the blood–brain barrier contributes to neurobehavioral changes observed in rheumatic heart disease
Sydenham chorea (SC) is the neurological manifestation associated with acute rheumatic fever (ARF). ARF and rheumatic heart disease (RHD) are autoimmune complications triggered by a group A streptococcal (GAS) infection. In ARF/RHD and SC, tissue cross‐reactive antibodies and T‐cells generated against GAS antigens have been implicated in the pathogenesis. In SC, antibodies against GAS antigens are known to cross‐react with neuronal proteins causing neurological manifestations including choreiform movements and neuropsychiatric symptoms such as irritability, attention deficit, and obsessive‐compulsive disorder. Previous studies in a rat autoimmune valvulitis (RAV) model of RHD, have shown that injection of streptococcal M protein could cause both cardiac and neurological symptoms. In this study it was shown that adoptive transfer of serum with anti‐GAS M antibodies to naive rats caused carditis but failed to demonstrate neurobehavioral symptoms. However, when the blood–brain barrier (BBB) was disrupted using lipopolysaccharide, all animals that received anti‐GAS M protein antibodies, developed neurobehavioral defects in addition to carditis. This highlights that impaired BBB integrity is essential for the development of neurobehavioral symptoms. The use of the RAV model and the disruption of BBB required for the development of neurobehavioral changes provides a platform to further investigate the mechanisms that lead to antibodies binding to basal ganglia structures that cause SC.
- Open Access
- 4 February 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-10
Streptococcus pyogenes vaccine candidates do not induce autoimmune responses in a rheumatic heart disease model
We have developed a candidate vaccine to protect against multiple strains of Streptococcus pyogenes infections. The candidate vaccine contains two synthetic peptides derived from S. pyogenes proteins: the M-protein epitope, p*17 and the IL-8 degrading S. pyogenes Cell-Envelope Proteinase (SpyCEP) epitope, K4S2. In this study we utilise a rat autoimmune valvulitis model that displays both the cardiac and neurobehavioural pathology associated with post-streptococcal sequelae, to assess if the vaccine candidate antigens induce autoimmune complications and inflammatory pathology. Each antigen was conjugated to carrier protein diphtheria toxoid (DT) and independently assessed for potential to induce autoimmune pathology in female Lewis rats. Rats were administered three subcutaneous doses, and one intranasal dose over a four-week study with a two-week recovery period. A positive control group received recombinant S. pyogenes M5 (rM5) protein, and the negative control group received PBS. Rats that received rM5 developed significant cardiac and neurological pathologies. There was no evidence of these pathologies in the PBS control group, or the rats administered either P*17-DT or K4S2-DT. This study provides further preclinical evidence of the safety of the vaccine candidates p*17 and K4S2 and their appropriateness as candidates in human clinical trials.
- 4 February 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-10
Open AccessStreptococcus pyogenes vaccine candidates do not induce autoimmune responses in a rheumatic heart disease model
We have developed a candidate vaccine to protect against multiple strains of Streptococcus pyogenes infections. The candidate vaccine contains two synthetic peptides derived from S. pyogenes proteins: the M-protein epitope, p*17 and the IL-8 degrading S. pyogenes Cell-Envelope Proteinase (SpyCEP) epitope, K4S2. In this study we utilise a rat autoimmune valvulitis model that displays both the cardiac and neurobehavioural pathology associated with post-streptococcal sequelae, to assess if the vaccine candidate antigens induce autoimmune complications and inflammatory pathology. Each antigen was conjugated to carrier protein diphtheria toxoid (DT) and independently assessed for potential to induce autoimmune pathology in female Lewis rats. Rats were administered three subcutaneous doses, and one intranasal dose over a four-week study with a two-week recovery period. A positive control group received recombinant S. pyogenes M5 (rM5) protein, and the negative control group received PBS. Rats that received rM5 developed significant cardiac and neurological pathologies. There was no evidence of these pathologies in the PBS control group, or the rats administered either P*17-DT or K4S2-DT. This study provides further preclinical evidence of the safety of the vaccine candidates p*17 and K4S2 and their appropriateness as candidates in human clinical trials.
- Open Access
- 2 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0272415
Clinical and epidemiological characteristics of influenza virus infection in hospitalized children with acute respiratory infections in Sri Lanka
Influenza viruses (Inf-V) are an important cause of acute respiratory infection (ARI) in children. This study was undertaken to describe the clinical and epidemiological characteristics of Inf-V infections in a sample of hospitalized children with ARI. Nasopharyngeal aspirates (NPA) from 500 children between 1 month to 5 years old with symptoms of ARI were collected at the Teaching Hospital Kegalle Sri Lanka From May 2016 to June 2018, NPAs were tested for influenza A (Inf-A) and B (Inf-B) viruses, human respiratory syncytial virus (hRSV), human parainfluenza virus (hPIV) 1–3 using an immunofluorescence assay. The Inf-V were then subtyped using a multiplex RT-PCR. Inf-V were detected in 10.75% (54/502) of the hospitalized children with ARI and in that 5.57% (28/502) were positive for Inf-A and 5.17% (26/502) were positive for Inf-B. Of the 54 Inf-V positive children, 33 were aged between 6 and 20 months. Of the 28 children infected with Inf-A, 15 had uncharacterized lower respiratory infection, 7 had bronchopneumonia and 6 had bronchiolitis. Of the 26 children infected with Inf-B, 11 had uncharacterized lower respiratory infection, 10 had bronchiolitis, and 4 had bronchopneumonia. Inf-B circulated throughout the year with a few peaks, one in June and then in August followed by November to December in 2016 and one in April 2017 and January 2018. Inf-A circulated throughout the year with a major peak in March to April 2017 and July 2018. ARI was more common in boys compared to girls. Majority of the children infected with Inf-V were diagnosed with uncharacterized lower respiratory infection and mild to moderate bronchiolitis. Inf-V infections were prevalent throughout the year in the study area of Sri Lanka with variations in the type of the circulating virus.
- 2 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0272415
Open AccessClinical and epidemiological characteristics of influenza virus infection in hospitalized children with acute respiratory infections in Sri Lanka
Influenza viruses (Inf-V) are an important cause of acute respiratory infection (ARI) in children. This study was undertaken to describe the clinical and epidemiological characteristics of Inf-V infections in a sample of hospitalized children with ARI. Nasopharyngeal aspirates (NPA) from 500 children between 1 month to 5 years old with symptoms of ARI were collected at the Teaching Hospital Kegalle Sri Lanka From May 2016 to June 2018, NPAs were tested for influenza A (Inf-A) and B (Inf-B) viruses, human respiratory syncytial virus (hRSV), human parainfluenza virus (hPIV) 1–3 using an immunofluorescence assay. The Inf-V were then subtyped using a multiplex RT-PCR. Inf-V were detected in 10.75% (54/502) of the hospitalized children with ARI and in that 5.57% (28/502) were positive for Inf-A and 5.17% (26/502) were positive for Inf-B. Of the 54 Inf-V positive children, 33 were aged between 6 and 20 months. Of the 28 children infected with Inf-A, 15 had uncharacterized lower respiratory infection, 7 had bronchopneumonia and 6 had bronchiolitis. Of the 26 children infected with Inf-B, 11 had uncharacterized lower respiratory infection, 10 had bronchiolitis, and 4 had bronchopneumonia. Inf-B circulated throughout the year with a few peaks, one in June and then in August followed by November to December in 2016 and one in April 2017 and January 2018. Inf-A circulated throughout the year with a major peak in March to April 2017 and July 2018. ARI was more common in boys compared to girls. Majority of the children infected with Inf-V were diagnosed with uncharacterized lower respiratory infection and mild to moderate bronchiolitis. Inf-V infections were prevalent throughout the year in the study area of Sri Lanka with variations in the type of the circulating virus.
- Open Access
- 20 July 2022
- Published by Wiley in Immunology & Cell Biology
- Vol. 100 (8) , 653-666
Characterization of an experimental model to determine streptococcal M protein–induced autoimmune cardiac and neurobehavioral abnormalities
Group A streptococcal (GAS) infection is associated with a spectrum of autoimmune diseases including acute rheumatic fever/rheumatic heart disease (ARF/RHD) and neurobehavioral abnormalities. Antibodies against GAS M proteins cross‐react with host tissue proteins in the heart and brain leading to the symptomatology observed in ARF/RHD. As throat carriage of Streptococcus dysgalactiae subspecies equisimilis (SDSE) has been reported to be relatively high in some ARF/RHD endemic regions compared with GAS, and both SDSE and GAS express coiled‐coil surface protein called M protein, we hypothesized that streptococci other than GAS can also associated with ARF/RHD and neurobehavioral abnormalities. Neurobehavioral assessments and electrocardiography were performed on Lewis rats before and after exposure to recombinant GAS and SDSE M proteins. Histological assessments were performed to confirm inflammatory changes in cardiac and neuronal tissues. ELISA and Western blot analysis were performed to determine the cross‐reactivity of antibodies with host connective, cardiac and neuronal tissue proteins. Lewis rats injected with M proteins either from GAS or SDSE developed significant cardiac functional and neurobehavioral abnormalities in comparison to control rats injected with phosphate‐buffered saline. Antibodies against GAS and SDSE M proteins cross‐reacted with cardiac, connective and neuronal proteins. Serum from rats injected with streptococcal antigens showed higher immunoglobulin G binding to the striatum and cortex of the brain. Cardiac and neurobehavioral abnormalities observed in our experimental model were comparable to the cardinal symptoms observed in patients with ARF/RHD. Here for the first time, we demonstrate in an experimental model that M proteins from different streptococcal species could initiate and drive the autoimmune‐mediated cardiac tissue damage and neurobehavioral abnormalities.
- 20 July 2022
- Published by Wiley in Immunology & Cell Biology
- Vol. 100 (8) , 653-666
Open AccessCharacterization of an experimental model to determine streptococcal M protein–induced autoimmune cardiac and neurobehavioral abnormalities
Group A streptococcal (GAS) infection is associated with a spectrum of autoimmune diseases including acute rheumatic fever/rheumatic heart disease (ARF/RHD) and neurobehavioral abnormalities. Antibodies against GAS M proteins cross‐react with host tissue proteins in the heart and brain leading to the symptomatology observed in ARF/RHD. As throat carriage of Streptococcus dysgalactiae subspecies equisimilis (SDSE) has been reported to be relatively high in some ARF/RHD endemic regions compared with GAS, and both SDSE and GAS express coiled‐coil surface protein called M protein, we hypothesized that streptococci other than GAS can also associated with ARF/RHD and neurobehavioral abnormalities. Neurobehavioral assessments and electrocardiography were performed on Lewis rats before and after exposure to recombinant GAS and SDSE M proteins. Histological assessments were performed to confirm inflammatory changes in cardiac and neuronal tissues. ELISA and Western blot analysis were performed to determine the cross‐reactivity of antibodies with host connective, cardiac and neuronal tissue proteins. Lewis rats injected with M proteins either from GAS or SDSE developed significant cardiac functional and neurobehavioral abnormalities in comparison to control rats injected with phosphate‐buffered saline. Antibodies against GAS and SDSE M proteins cross‐reacted with cardiac, connective and neuronal proteins. Serum from rats injected with streptococcal antigens showed higher immunoglobulin G binding to the striatum and cortex of the brain. Cardiac and neurobehavioral abnormalities observed in our experimental model were comparable to the cardinal symptoms observed in patients with ARF/RHD. Here for the first time, we demonstrate in an experimental model that M proteins from different streptococcal species could initiate and drive the autoimmune‐mediated cardiac tissue damage and neurobehavioral abnormalities.